BW

Matriptase (K21) polyclonal Antibody | BS2574

(No reviews yet) Write a Review
SKU:
BW-BS2574
Availability:
Usually ships in 5 working days
£732.00 - £1,098.00

Description

Matriptase (K21) polyclonal Antibody | BS2574 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC IF IP

Application Range: WB: 1:500~1:1000 IHC/IF: 1:50~1:200 IP: 1:10~1:100

Background: Matriptase (also known as MT-SP1, ST14, prostamin and epithin in mouse) is a tumor-associated type II transmembrane serine protease that is highly expressed in many human cancer-derived cell lines and is implicated in extracellular matrix re-modeling, tumor growth, and metastasis. Matriptase performs pleiotropic functions in the development of the epidermis, hair follicles, and cellular immune system. Sphingosine 1-phosphate (S1P, SPP), present in serum-derived lipoproteins, activates matriptase while matriptase activates both urokinase-type plasminogen activator and hepatocyte growth factor (HGF) . Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a Kunitz-type serine protease inhibitor identified as a strong inhibitor of matriptase and HGF.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Matriptase (K21) polyclonal Antibody detects endogenous levels of Matriptase protein.

Molecular Weight: ~ 90 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Suppressor of tumorigenicity 14 protein; Matriptase; Membrane-type serine protease 1; MT-SP1; Prostamin; Serine protease 14; Serine protease TADG-15; Tumor-associated differentially-expressed gene 15 protein; ST14; PRSS14; SNC19; TADG15

Immunogen: Synthetic peptide, corresponding to the N-terminual of Human Matriptase.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway:

View AllClose